Recent News

• 11.03.2026 - Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
• 10.13.2026 - Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
• 09.30.2026 - Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
• 09.03.2026 - FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
• 09.02.2026 - Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
• 09.01.2026 - Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
• 08.12.2026 - Liquidia Corporation Reports Second Quarter 2026 Financial Results
• 07.29.2026 - Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
• 06.11.2026 - Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
• 06.08.2026 - Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index

Recent Filings

• 10.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.14.2026 - 8-K Current report
• 10.14.2026 - EX-99.1 EX-99.1
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 10.13.2026 - 4 Statement of changes in beneficial ownership of securities